Nectar Social | $10,600,000 | (Jun 6, 2025)
Baobab | $13,702,071 | (Jun 6, 2025)
Signify Bio | $15,000,000 | (Jun 6, 2025)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
Voltrac | $2,286,772 | (Jun 6, 2025)
Rosebud | $6,000,000 | (Jun 6, 2025)
Allay Therapeutics | $57,500,000 | (Jun 6, 2025)
Impart Security | $12,000,000 | (Jun 6, 2025)
Flank | $10,000,000 | (Jun 6, 2025)
Obvio | $22,000,000 | (Jun 5, 2025)
Filament Syfter | $4,800,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)